Life Sciences Should Brace For Fla. Rad Source Ruling

Law360, New York (March 26, 2014, 10:55 PM EDT) -- Some of the most innovative new products arising out of the life sciences industry have passed through multiple hands before reaching physicians, caregivers and patients. Insights and early discoveries in academic laboratories are often validated, translated and tested by small companies and, upon proof-of-concept, those products are then frequently licensed to large, global companies for commercialization. Not surprisingly, intellectual property rights covering those products are conveyed throughout the discovery and development value chain through license arrangements.

Generally speaking, exclusive licenses to intellectual property rights covering life...
To view the full article, register now.